Compare Natera Inc. Common Stock (NTRA) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ferrari NV — how do they compare? Natera Inc. Common Stock trades at $402.1 (market cap $57.03B), while Ferrari NV trades at $396.35 (market cap $68.43B). The key difference: Ferrari NV is the larger of the two by market cap, and Ferrari NV pays a 1.09% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ferrari NV for 126 Days on average.
| NTRA | RACE | |
|---|---|---|
Market Cap | $57.03B | $68.43B |
Volume | 1,131,157 | 343,086 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $436.54 |
52-Week Low | $179.42 | $314.63 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $56.18B | $70.30B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Ferrari (RACE) trades at $395.23, up 0.93% with strong fundamentals including 22.25% net margins and 45.45% ROE. The stock shows consistent earnings beats with Q2 2026 EPS of $2.99 exceeding expectations. Technical indicators signal bearish momentum near key resistance at $395, while analyst consensus remains strongly bullish with a $462.75 price target. Recent news highlights institutional accumulation and a €250 million share buyback program.
Outlook remains positive given premium brand positioning and operational efficiency, though high valuation multiples (P/E 37.41) and technical resistance pose near-term risks. The combination of shareholder returns via buybacks and sustained profitability supports long-term growth potential despite macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
